[1] J. W. Funder, R. M. Carey, C. Fardella, C. E. Gomez-Sanchez, F. Mantero, M. Stowasser, W. F. Young Jr. and V. M. Montori, “Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline,” Journal of Clinical Endocrinology & Metabolism, Vol. 93, No. 9, 2008, pp. 3266-3281.
http://dx.doi.org/10.1210/jc.2008-0104
[2] S. C. Murphy, S. Agger and P. M. Rainey, “Too Much of a Good Thing: A Woman with Hypertension and Hypokalemia,” Clinical Chemistry, Vol. 55, No. 12, 2009, pp. 2093-2096.
http://dx.doi.org/10.1373/clinchem.2009.127506
[3] P. C. White, T. Mune and A. K. Agarwal, “11-Beta-hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess,” Endocrine Reviews, Vol. 18, No. 1, 1997, pp. 135-136.
http://dx.doi.org/10.1210/er.18.1.135
[4] Scientific Committee on Food, “Opinion of the Scientific Committee on Food on Glycyrrhizinic Acid and Its Ammonium Salt,” European Commission Heath and Consumer Protection Directorate General, Brussels, 2012.
[5] H. A. Sigurjonsdottir, K. Manhem, M. Axelson and S. Wallerstedt, “Subjects with Essential Hypertension Are More Sensitive to the Inhibition of 11 Beta-HSD by Liquorice,” Journal of Human Hypertension, Vol. 17, 2003, pp. 125-131. http://dx.doi.org/10.1038/sj.jhh.1001504